TY - JOUR
T1 - Sympathetic Ophthalmia - An Overview
AU - Agarwal, Mamta
AU - Radosavljevic, Aleksandra
AU - Tyagi, Mudit
AU - Pichi, Francesco
AU - Al Dhanhani, Aisha A.
AU - Agarwal, Aditi
AU - Cunningham, Emmett T.
N1 - Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
PY - 2023
Y1 - 2023
N2 - Introduction: Sympathetic ophthalmia (SO) is rare, bilateral granulomatous panuveitis that typically occurs following penetrating or perforating ocular trauma or surgery. This review aims to provide an update on the etiopathogenesis, clinical presentations, diagnosis and treatment of SO. Methods: Reports cited in MEDLINE database, that analyzed SO in at least 5 patients, published prior to December 1st, 2021 were included. Results: Initially, SO was associated with penetrating ocular trauma, however, various studies reported an increased incidence of SO after surgical procedures including vitreoretinal surgeries. Multimodal imaging including fluorescein and indocyanine green angiography, optical coherence tomography (OCT) and OCT angiography have added further insights into the understanding of SO. While pulse dose corticosteroids & immunosuppressive drugs are still the treatment of choice, TNF-α blockers & other biologic drugs represent new promising agents. Conclusion: There is a growing pool of evidence in understanding the pathogenesis of SO. Novel treatment options have provided better prognosis for this potentially blinding condition.
AB - Introduction: Sympathetic ophthalmia (SO) is rare, bilateral granulomatous panuveitis that typically occurs following penetrating or perforating ocular trauma or surgery. This review aims to provide an update on the etiopathogenesis, clinical presentations, diagnosis and treatment of SO. Methods: Reports cited in MEDLINE database, that analyzed SO in at least 5 patients, published prior to December 1st, 2021 were included. Results: Initially, SO was associated with penetrating ocular trauma, however, various studies reported an increased incidence of SO after surgical procedures including vitreoretinal surgeries. Multimodal imaging including fluorescein and indocyanine green angiography, optical coherence tomography (OCT) and OCT angiography have added further insights into the understanding of SO. While pulse dose corticosteroids & immunosuppressive drugs are still the treatment of choice, TNF-α blockers & other biologic drugs represent new promising agents. Conclusion: There is a growing pool of evidence in understanding the pathogenesis of SO. Novel treatment options have provided better prognosis for this potentially blinding condition.
KW - Immunosuppression
KW - ocular trauma
KW - panuveitis
KW - sympathetic ophthalmia
KW - vitreoretinal surgery
UR - http://www.scopus.com/inward/record.url?scp=85130590983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130590983&partnerID=8YFLogxK
U2 - 10.1080/09273948.2022.2058554
DO - 10.1080/09273948.2022.2058554
M3 - Review article
C2 - 35579612
AN - SCOPUS:85130590983
SN - 0927-3948
VL - 31
SP - 793
EP - 809
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 4
ER -